Accepted for Publication: March 4, 2011.
Published Online: May 9, 2011. doi:10.1001/archneurol.2011.105
Author Contributions: Dr Fagan had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Fagan, Vanderstichele, Trojanowski, and Holtzman. Acquisition of data: Fagan, Vanderstichele, Mintun, and Morris. Analysis and interpretation of data: Fagan, Shaw, Xiong, Vanderstichele, Mintun, Coart, and Holtzman. Drafting of the manuscript: Fagan and Trojanowski. Critical revision of the manuscript for important intellectual content: Shaw, Xiong, Vanderstichele, Mintun, Trojanowski, Coart, Morris, and Holtzman. Statistical analysis: Xiong and Coart. Obtained funding: Fagan, Mintun, Morris, and Holtzman. Administrative, technical, and material support: Fagan, Shaw, Vanderstichele, Trojanowski, and Morris. Study supervision: Fagan and Holtzman.
Financial Disclosure: Dr Shaw reports consulting for Innogenetics NV. Dr Vanderstichele is an employee of Innogenetics NV, the manufacturer of the cerebrospinal fluid assays used in the present study. He has no further financial involvement in the company, nor does he receive benefits related to the sales of the assays or publication of manuscripts. Dr Mintun is currently Chief Medical Officer at Avid Radiopharmaceuticals (a subsidiary of Eli Lilly), which is developing a non–Pittsburgh compound B radiopharmaceutical to image amyloid plaques. Dr Coart is an employee of Innogenetics NV, the manufacturer of the cerebrospinal fluid assays used in the present study. He has no further financial involvement in the company, nor does he receive benefits related to the sales of the assays or publication of manuscripts. Dr Holtzman reports consulting for Innogenetics NV and is on the scientific advisory board of En Vivo, Satori, and C2N Diagnostics.
Funding/Support: This study was supported by grants P50 AG05681 (Dr Morris), P01 AG03991 (Dr Morris), P01 AG026276 (Drs Morris and Fagan), P30 NS057105 (Dr Holtzman), P30 NS048056 (Dr Mintun), UL1 RR024992 (Dr Mintun), U01 AG024904 (Drs Trojanowski and Shaw), 1RC AG036535 (Drs Trojanowski and Shaw), and AG10124 (Dr Trojanowski) from the National Institutes of Health; the Dana Foundation (Dr Mintun); and the Charles and Joanne Knight Alzheimer’s Research Initiative (Dr Morris).
Disclaimer: The funding organizations did not have any role in the design or conduct of the study, the collection, management, analysis or interpretation of the data, or the preparation, review or approval of the manuscript.
Additional Contributions: We thank the Knight Alzheimer’s Disease Research Center Biomarker, Clinical, Genetics, and Imaging Cores and the Alzheimer’s Disease Neuroimaging Initiative Biomarker Core.